Raphael Dahmen
Sanofi (Germany)(DE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes, Diabetes and associated disorders, Cardiovascular Function and Risk Factors
Most-Cited Works
- → New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1(2014)405 cited
- → Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF(2021)109 cited
- → Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml(2014)106 cited
- → Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes(2012)104 cited
- → Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes(2017)94 cited
- → Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes(2014)93 cited
- → Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator(2016)33 cited
- → Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study(2022)27 cited
- → Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes(2016)10 cited
- Hormonal inducibility of liver-specific enzymes in cultured rat embryos.(1986)